Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 2005

View Archived Issues

Adderall XR improves symptoms and quality of life of adult patients with ADHD

Phase I study data indicate ATI-7505 is safe

Uluru established to develop innovative oral and topical products

Maruho to develop and market DepoBupivacaine in Japan

Maruho and Toray enter codevelopment agreement for TRK-820 in Europe

Intercell receives milestone payment from Merck for bacterial vaccine candidate

NicOx and Merck extend NO-donating compound research collaboration

Crucell inlicenses bacterial antigens for antibody development

Roche and Protein Design Labs expand daclizumab agreement

Phase II study of Hemopure in lower limb amputation cleared to begin in U.K.

FM-VP4 begins phase II hypercholesterolemia study

Transition Therapeutics acquires drug discovery technology and assets of Protana

BrachySil phase IIb trials begin for liver cancer

Schering-Plough presents overview of developmental programs

Merck & Co. wins Vioxx liability case

Bicalutamide improves survival of patients with locally advanced prostate cancer

Miglustat shows promise in the management of children with Niemann-Pick disease

Good safety and pharmacokinetic profile of bimosiamose in healthy subjects

Clinical data supports the use of extended-release methylphenidate in ADHD

Recent patents disclose novel agents for the treatment of diabetes

HIV protease inhibitors imparted in recent Sequoia patent

Melanocortin receptor agonist emerges from Astellas Pharma R&D

New treatment options for neuropsychiatric disorders claimed in recent patent literature

Estrogen receptor modulators for hot flushes prepared and tested at Merck & Co.

Spinocerebellar ataxia type 5 caused by spectrin SPTBN2 mutations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...